Home / Pharmaceutical / Pneumococcal Vaccines Market By Vaccine (Pneumococcal Conjugate Vaccine, Pneumococcal Polysaccharide Vaccine), By Product (10-Valent PCV, 13-valent PCV, 23-valent PPSV) - Growth, Future Prospects & Competitive Analysis, 2021 - 2029

Pneumococcal Vaccines Market By Vaccine (Pneumococcal Conjugate Vaccine, Pneumococcal Polysaccharide Vaccine), By Product (10-Valent PCV, 13-valent PCV, 23-valent PPSV) - Growth, Future Prospects & Competitive Analysis, 2021 - 2029

Industry Outlook

The global pneumococcal vaccines market held US$ 7,108.7 Mn in 2020 and expected to grow at compound annual growth rate (CAGR) of 5.1% during the forecast period from 2021 to 2029. Pneumococcal diseases are one of the leading cause of serious illness globally resulting in high number of hospitalization every year. Diseases caused by pneumococcus bacteria include pneumonia, otitis media, sinus, meningitis and sepsis. According to National Foundation of Infectious Diseases (NFID), more than one million adults in the U.S. suffer from pneumococcal pneumonia every year and close to half a million people hospitalizations occur annually in the United States. The burden of pneumococcal diseases is higher in children below 5 years old and adults above 65 years. Developing countries are the most affected by pneumococcal diseases, for instance, India holds the highest number of global pneumonia deaths, accounting for 20 percent of worldwide pneumonia deaths in children below the age of 5. However, constant initiatives by government across the world and private health organizations there has been significant reduction in number deaths occurring, especially in the developing countries.

Pneumococcal Vaccines Market

The market players operating in the market are focusing on low income countries and developing countries by investing and partnering with local players to maintain the supply of vaccines in the region. North America held the largest share in the global pneumococcal vaccines market owing to the domicile of two major pneumococcal vaccines producers (Pfizer, Inc. and Merck & Co., Inc.) in the region. Pneumococcal conjugate vaccines produced by these pharma giants is part of the routine vaccine program in the U.S. and Canada. Asia Pacific and Latin America are projected to witness significant growth during the forecast period owing to high burden of pneumococcal diseases in the region and supportive government policies rendering market growth.

"13-valent PCV Set to Drive the Market of Pneumococcal Vaccines Market"

In 2020, 13-valent PCV vaccine held the largest share in the global pneumococcal vaccines market. PVC13 offers a significant benefit for preventing pneumonia and invasive diseases caused by Streptococcus pneumonia in adults and children. The Centers for Disease Control and Prevention (CDC) PCV13 vaccines for children below 2 and adults above 65 years of age. Moreover, it is now recommended that adults above 65 and older to get both PCV13 and PPSV23 vaccine for better immunogenicity against various serotypes of pneumococcus. Moreover, Pfizer’s 20-valent PCV and Merck’s 15-valent PCV are in the late stage of the clinical trials and expected to enter the market during the forecast period, which will further provide thrust to pneumococcal market.

The key players currently engaged in pneumococcal vaccines market include Pfizer, Inc., Merck & Co., Inc. and GlaxoSmithKline plc.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Pneumococcal Vaccines market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Pneumococcal Vaccines market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Research Period  2020-2030
Base Year 2021
Forecast Period  2022-2030
Historical Year  2020
Unit  USD Million
  • Pneumococcal Conjugate Vaccine
  • Pneumococcal Polysaccharide Vaccine

  • 10-valent PCV
  • 13-valent PCV
  • 23-valent PPSV
  • Pipeline Analysis
    • Phase III Analysis
      • 15-valent PCV
      • 20-valent PCV
    • Tabular Representation of Phase I and Phase II Vaccines

 Region Segment (2020–2030; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa
Global Impact of Covid-19 Segment (2020-2021; US$ Million )
  • Pre Covid-19 situation
  • Post Covid-19 situation

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Pneumococcal Vaccines market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Pneumococcal Vaccines market?
  • Which is the largest regional market for Pneumococcal Vaccines market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Pneumococcal Vaccines market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Pneumococcal Vaccines market worldwide?
Choose License Type
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +